⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
United States Cardiovascular Devices Market Size, Share, Trends and Forecast 2026-2034 | Market to Reach US$32.62 Billion as AI Monitoring and Minimally Invasive Care Accelerate
globenewswire.com
ABT
BSX
EW
CAH
MDT
GEHC
JNJ
Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer
globenewswire.com
AZN
GILD
MRK
PFE
BMY
JNJ
TEVA
Eine neue modellbasierte Analyse untermauert das Potenzial von TECVAYLI®▼ (teclistamab) in Kombination mit daratumumab, die Erwartungen hinsichtlich des Langzeitüberlebens bei einem rezidivierten bzw. refraktären multiplen Myelom in frühen
globenewswire.com
JNJ
Une nouvelle analyse modélisée renforce le potentiel de TECVAYLI®▼ (teclistamab) associé au daratumumab pour redéfinir les perspectives de survie à long terme dans le myélome multiple en rechute/réfractaire dans les premières lignes de traitement
globenewswire.com
JNJ
Global TDP-43 Antibody Market Outlook and Forecast, 2026-2032 - Market to Reach USD 508.93 Million at 12.03% CAGR as Validated Antibodies, AI-Powered Imaging, and Neurodegenerative Research Create New Growth Opportunities
globenewswire.com
ABBV
ABT
ABM
BIO
BIIB
BMRN
CRSP
DHR
EXAS
GILD
ILMN
INCY
ISRG
JNJ
LULU
MDLZ
MRK
NVS
PFE
REGN
ROST
SNPS
SRPT
STX
TMO
TSLA
VRTX
WDC
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
prnewswire.com
JNJ
Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
globenewswire.com
JNJ
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
prnewswire.com
JNJ
Global Autoimmune Treatment Market to Reach USD 321.95 Billion by 2034, Driven by Rising Prevalence of Autoimmune Diseases, Growing Adoption of Biologics, and Advances in Precision Medicine Says Maximize Market Research
prnewswire.com
ABBV
JNJ
AMGN
BMY
PFE
NVS
SNY
LLY
AZN
UCB
BIIB
VTRS
GILD
KYMR
Global Multiple Sclerosis Treatment Market to Grow at 5.8% CAGR, Reaching USD 44.45 Billion by 2034 as Advanced Therapies and Disease-Modifying Treatments Gain Momentum, Says Maximize Market Research
prnewswire.com
NVS
BIIB
SNY
MRK
BMY
JNJ
TEVA
VTRS
AMGN